Drug Profile
ARCT 165
Alternative Names: ARCT-165Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Arcturus Therapeutics
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 30 Aug 2021 Phase-I/II clinical trials in COVID-2019 infections (Prevention, In adults, In the elderly) in Singapore (IM) (NCT05037097)
- 09 Aug 2021 ARCT 165 is available for licensing as of 03 Aug 2021. https://arcturusrx.com/mrna-medicines-business-development/
- 03 Aug 2021 Arcturus Therapeutics plans a phase I/II trial in COVID-2019 infections (Prevention) in Singapore